Tag: antiplatelet therapy
-
Understanding COP-INH: A New Marker for Post-PCI Risk in ACS Patients
Introduction Dual antiplatelet therapy (DAPT), pairing aspirin with a P2Y12 receptor antagonist, is a cornerstone after percutaneous coronary intervention (PCI) with drug-eluting stents. While effective at reducing stent thrombosis and major adverse cardiac events (MACE), patient responses to clopidogrel and aspirin vary. High residual platelet reactivity (HRPR) after clopidogrel treatment correlates with worse outcomes, underscoring…
-
COP-INH Score: A New Way to Predict Post-PCI Risks in ACS Patients
Understanding the Need for Better Post-PCI Risk Prediction Dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 receptor antagonist, is standard after percutaneous coronary intervention (PCI) with drug-eluting stents. While this approach reduces stent thrombosis and major adverse cardiac events (MACE), individual responses to antiplatelet drugs vary widely. High residual platelet reactivity (HRPR) after clopidogrel…
-
COP-INH Score: A New Metric for Predicting Post-PCI Outcomes in ACS Patients
Understanding the Challenge: Platelet Reactivity After PCI Dual antiplatelet therapy (DAPT), typically aspirin plus a P2Y12 receptor antagonist, is standard care after percutaneous coronary intervention (PCI) with drug-eluting stents. While this regimen reduces stent thrombosis and major adverse cardiac events (MACE), patient responses vary. High residual platelet reactivity (HRPR) after clopidogrel therapy has been linked…